For Investors: MNKD needs a year or two to really get it going and most on this board are in agreement with that timeline. It's simply ridiculous to be expect more at this very early stage of a soft launch. Afezza is a brand new, disruptive, inhaled insulin that needs time to be embraced by the diabetic community. And, it will. Why? Because it works like no other insulin before, mimicking the pancreas to perfection with NO sugar lows! Yay!!!
News 
Market Data 
Discover 
